Pentamer-positive CD8+ T cells infused
| Patient no. . | Peptide/HLA . | Pentamer+/CD8+ PB donor, % . | Pentamer+/CD8+ first dose, % . | Pentamer+/CD8+ second dose, % . | Pentamer+/CD8+ third dose, % . |
|---|---|---|---|---|---|
| 7 | PR1/A2 | ND | 0.02 | 0.03 | ND |
| 8 | BCR-ABL/A3 | 0.02 | 0.03 | 0.03 | 0.16 |
| BCR-ABL/A11 | 0.63 | 0.4 | 0.06 | 0.1 | |
| 9 | BCR-ABL/A11 | 0.45 | 0.10 | 0.26 | 0.15 |
| 10 | BCR-ABL/B8 | 0.05 | 0.24 | 0.14 | NT |
| 11 | BCR-ABL/A3 | 0.01 | 16.9 | 21.8 | 3.1 |
| PR1/A2 | ND | 0.04 | 0.02 | 0.04 | |
| WT1/A2 | 0.01 | 0.05 | 0.05 | 0.06 | |
| 12 | PR1/A2 | ND | 0.97 | 6.64 | 11.03 |
| WT1/A2 | ND | 0.81 | 0.21 | 0.04 | |
| 13 | WT1/A24 | 0.03 | 0.05 | 0.05 | 0.18 |
| 14 | PR1/A2 | 0.48 | 0.39 | 0.09 | 0.03 |
| WT1/A2 | 0.36 | 5.7 | 9.4 | 9.3 |
| Patient no. . | Peptide/HLA . | Pentamer+/CD8+ PB donor, % . | Pentamer+/CD8+ first dose, % . | Pentamer+/CD8+ second dose, % . | Pentamer+/CD8+ third dose, % . |
|---|---|---|---|---|---|
| 7 | PR1/A2 | ND | 0.02 | 0.03 | ND |
| 8 | BCR-ABL/A3 | 0.02 | 0.03 | 0.03 | 0.16 |
| BCR-ABL/A11 | 0.63 | 0.4 | 0.06 | 0.1 | |
| 9 | BCR-ABL/A11 | 0.45 | 0.10 | 0.26 | 0.15 |
| 10 | BCR-ABL/B8 | 0.05 | 0.24 | 0.14 | NT |
| 11 | BCR-ABL/A3 | 0.01 | 16.9 | 21.8 | 3.1 |
| PR1/A2 | ND | 0.04 | 0.02 | 0.04 | |
| WT1/A2 | 0.01 | 0.05 | 0.05 | 0.06 | |
| 12 | PR1/A2 | ND | 0.97 | 6.64 | 11.03 |
| WT1/A2 | ND | 0.81 | 0.21 | 0.04 | |
| 13 | WT1/A24 | 0.03 | 0.05 | 0.05 | 0.18 |
| 14 | PR1/A2 | 0.48 | 0.39 | 0.09 | 0.03 |
| WT1/A2 | 0.36 | 5.7 | 9.4 | 9.3 |
HLA indicates human leukocyte antigen; ND, not detectable; and NT, not tested.